💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Acetophenazine Maleate

CHEMBL2360079 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
643.7 g/mol
LogP
—
Phase
4

As the maleate salt of a first-generation phenothiazine, acetophenazine maleate carries the dopamine-blocking mechanism and the adverse effect profile of the parent drug unchanged. Historical use covered schizophrenia and related psychotic disorders. The concern specific to prolonged exposure is tardive dyskinesia, a movement disorder that may persist after the drug is stopped and that distinguishes long-term risk from the acute extrapyramidal reactions seen early in treatment. Second-generation antipsychotics have replaced this formulation, and it is no longer commonly prescribed. The salt is recorded with the formula C31H37N3O10S and a formula mass near 643.7 g/mol, its development having reached the final clinical phase.

The maleate salt form of acetophenazine, an older phenothiazine antipsychotic used historically for schizophrenia and related psychotic disorders. It shares the same dopamine-blocking mechanism and side effect profile as acetophenazine, including the risk of tardive dyskinesia with long-term use. This formulation is no longer commonly prescribed, having been replaced by second-generation antipsychotics.

Peso Molecular

643,7000 g/mol

TPSA

222,00 Ų

Áreas Terapêuticas

Psychiatry Schizophrenia

Mecanismo de Ação

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C23H29N3O2S.2C4H4O4/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27;2*5-3(6)1-2-4(7)8/h2-3,5-8,17,27H,4,9-16H2,1H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-

                

                

                

                    
                    

                        
Molecular Formula

                        
C31H37N3O10S

                    

                    
                    

                        
HBD / HBA

                        
5 / 14

                    

                    
                    

                        
Ligações Rotacionáveis

                        
11

                    

                    
                    
                    

                        
Átomos Pesados

                        
45

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
The maleate salt form of acetophenazine, an older phenothiazine antipsychotic used historically for schizophrenia and related psychotic disorders. It shares the same dopamine-blocking mechanism and side effect profile as acetophenazine, including the risk of tardive dyskinesia with long-term use. This formulation is no longer commonly prescribed, having been replaced by second-generation antipsychotics.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Acetophenazine Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2360079.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5281082.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.